BioPharma Dive October 21, 2024
Sponsored content By Altasciences
Cancer research is experiencing a paradigm shift with the introduction of innovative therapies like messenger RNA (mRNA)-based treatments and chimeric antigen receptor T-cell (CAR T) therapy. The development and use of immunotherapy and precision medicine have sparked global interest due to their potential to harness the body’s immune system to fight cancer more effectively. Both therapies have demonstrated promising outcomes in clinical trials, particularly in refractory cancers. “Advances in targeted cancer therapies are integral to improving overall remission rates and reducing damage to healthy tissues,” explains Dr. Beatrice Setnik, PhD, Chief Scientific Officer at Altasciences.
Crucial nonclinical data gathered from mRNA and CAR T-studies
Nonclinical studies in mRNA and CAR T-cell therapy are essential for evaluating...
Today's Sponsors
Today's Sponsor